Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

The FDA gave the go-ahead to Novocure for its tumor-treating electric fields device that targets advanced pancreatic cancer ...

The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...

The sentiment is ecstatic regarding this de-risking event. Will the stock maintain these gains, or is this a typical 'sell ...

The Swiss biopharmaceutical company’s shares surged in after-hours trading after it said the FDA approved its Optune Pax ...

Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer ...

NovoCure NVCR shares are popping on Thursday following a major FDA approval that sent the stock soaring nearly 30% in Wednesday's after‑hours trading. NovoCure stock is showing exceptional strength.

Optune Pax is a portable medical device that delivers TTFields non-invasively via wearable arrays to disrupt electrical processes essential for cancer cell division.